CAR-T therapies can be transformative against certain cancers, but they are slow and costly to make — each dose manufactured from an individual patient’s own immune cells. New research points to a way around that bottleneck: growing the needed cells from stem cells, at scale.
Researchers at Boston University’s Center for Regenerative Medicine and Boston Medical Center found that manipulating Notch signalling lets them reliably produce CD4+ helper T cells from induced pluripotent stem cells. The work appeared in Stem Cell Reports.
The manufacturing problem
Today’s CAR-T requires isolating a patient’s T cells, genetically engineering them, expanding them and returning them — a process taking weeks and costing hundreds of thousands of dollars per dose.
The consequences go beyond expense. Patients with aggressive cancer may deteriorate or die during the manufacturing window. Heavily pretreated patients sometimes have T cells too damaged by prior chemotherapy to engineer successfully. And each production run is bespoke, so quality varies between patients in ways that are difficult to control.
An off-the-shelf product — manufactured in advance, stored, available on demand — would address all three.
Why induced pluripotent stem cells
iPSCs are adult cells reprogrammed back to an embryonic-like state from which they can become any cell type. Two properties make them attractive here.
They are effectively unlimited: a single well-characterised iPSC line can be expanded indefinitely, so one starting cell bank could in principle supply enormous numbers of doses. And they can be engineered once — adding a chimeric antigen receptor and any other modifications at the stem cell stage, then differentiating — rather than engineering each patient’s cells separately.
The obstacle has consistently been differentiation. Coaxing iPSCs into genuinely functional T cells has proven difficult, and the cells produced have frequently been abnormal or restricted to limited subtypes.
The Notch trick
Notch signalling is essential for T-cell development — it is the pathway directing precursors down the T-cell lineage in the thymus. The standard approach therefore supplies Notch signals to push iPSCs toward T cells.
The insight here is about timing. The team found that removing Notch signalling during later maturation, while dialling down another signal, allowed developing cells to survive and mature into functional, diverse CD4+ T cells resembling those in blood.
That mirrors normal biology. Notch is required early and must be withdrawn for cells to complete maturation — maintaining it throughout, as simpler protocols do, arrests development. The advance is recognising that the signal must be switched off as deliberately as it was switched on.
“T cells that look like those from blood, with a full repertoire of the different subtypes,” is how principal investigator Gustavo Mostoslavsky described the output.
Why helper T cells specifically
Most attention in cell therapy goes to killer cells, which do the destroying. CD4+ helper T cells support and sustain that attack — providing the signals that keep killer cells functional, persistent and effective.
This matters more than it might appear. A recurring limitation of CAR-T is that infused cells sometimes fail to persist, disappearing within weeks and allowing relapse. Helper cell support is one of the factors influencing persistence, and clinical CAR-T products generally contain both populations rather than killer cells alone.
An off-the-shelf approach producing only killer cells would therefore be missing a component that may be essential to durable responses.
The problem this does not solve
Manufacturing is one barrier to off-the-shelf cell therapy. The other is rejection.
Cells derived from a donor iPSC line are foreign to the recipient, and a functioning immune system recognises and eliminates them — often before they have done their work. This is why allogeneic cell therapies have generally shown shorter persistence than patient-derived products.
Approaches exist — editing away the surface markers that mark cells as foreign, or intensifying conditioning to suppress the recipient’s immune system — but none is fully solved. A scalable source of functional T cells is necessary for off-the-shelf therapy and not sufficient for it.
What comes next
The team plans to add chimeric antigen receptors to their iPSC-derived cells and test them in animal models.
That is the sequence that matters. Producing cells resembling blood T cells is a developmental biology achievement; demonstrating that CAR-equipped versions kill tumours in a living animal is what makes it a therapeutic advance.
The caveats
This is early preclinical work. “Resembling those in blood” is characterisation by phenotype and gene expression, and functional equivalence in a patient is a higher bar. iPSC-derived cells have repeatedly proven subtly different from their natural counterparts in ways that only surface in demanding tests.
Reliable, scalable production of functional T cells from stem cells is nonetheless a key hurdle for the entire off-the-shelf field — and one of the few where a specific technical fix has now been described. Preclinical research; not medical advice.